Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC

Abstract

BackgroundThe aim of this survey was to acquire an overview of the current management of ovarian cancer with an emphasis on the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).Methods: An email was sent to Oncologists prior to PSOGI International Symposium on Advanced Ovarian Cancer, Athens 11–13 April 2019. Doctors submitted responses on the relevant website. The self-report survey contained 17 questions.ResultsIn total, 467 Medical Oncologists, Surgical Oncologists or Gynaecologic Oncologists were participated and answered to this survey. The resectability of disease was evaluated by laparoscopy from 48.5% of the participants, while 51.5% answered that they stage their patients pre-surgically with the use of CT or MRI. The preferred first intervention in advanced ovarian cancer patients is the neoadjuvant chemotherapy followed by interval cytoreductive surgery (72%). Regarding the use of HIPEC, almost half of the participants answered that there is role of HIPEC use in ovarian cancer patients undergoing interval debulking surgery, while almost 70% answered positively about the utility of HIPEC use in ovarian cancer recurrence. As for the role of lymphadenectomy in advanced ovarian cancer patients, half of the responders answered negatively. Finally, only 25% of the participants responded that they always check the BRCA status of their ovarian cancer patients, despite the possible differentiation of treatment based on the molecular profiling (80%).ConclusionsThe results of this survey indicate the utility of HIPEC in treatment of ovarian cancer patients and the differences in the overall management of ovarian cancer patients in the current clinical practice.

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?

“…Recent study from our group demonstrates the incidence of residual disease in 70% of cases (46). By definition in our study, the main sites of residual disease are, if we observed deposits in remain great omentum, liver rounge ligament, gallbladder and vaginal stump and recurrent disease included small bowel, mesenterium, pelvic floor, diaphragm (31).…”

“…The most important finding is the survival rates between residual and recurrent disease. Median survival rates in residual disease HIPEC group was 38 versus 26 m in recurrent HIPEC group (46).…”

Narrative review of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced ovarian cancer: a critical reappraisal of the current evidence

“…Yet, it presents superior outcomes in selected clinical settings as demonstrated by RCTs. According to a survey conducted by the study group of Spiliotis et al and based on questionnaires answered by 467 Medical, Surgical and Gynecologic oncologists, the proportion of physicians who considered there is a utility of HIPEC in the management of primary and recurrent EOC was approximately 50% and 70%, respectively (21).…”

Management of patients with advanced ovarian cancer – Role of complete cytoreduction and HIPEC: Attitudes of gynaecologist oncologists in two different continents

“…We recently published a similar study in Pleura and Peritoneum entitled ‘Survey on the current gynaecological approach of ovarian cancer patients – The utility of HIPEC’ 4 . An online survey was conducted after OVHIPEC‐1 and prior to Peritoneal Surface Oncology Group International Symposium on Advanced Ovarian Cancer, Athens 11–13 April 2019.…”